Comparative Review on Semaglutide vs. Trizepatide for the Treatment of Type 2 Diabetes
Abstract
Type 2 diabetes mellitus (T2DM) is a chronic metabolic disorder, which leads to elevated levels of blood sugar and is characterized by beta-cell malfunctioning and resistance to insulin. The pressure to find safer and more efficient treatment options has reached an urgent situation with a rapid growth of type 2 diabetes in the world population due to the failure of traditional antidiabetic drugs to manage weight and cardiovascular risk. The paper will review the pharmacological, clinical, safety, and efficacy of tirzepatide and semaglutide, novel incretin-based agents in the treatment of type 2 diabetes, and the cardiovascular benefits of semaglutide, which is a selective GLP-1 receptor agonist and to significantly improve glycemic control (reducing HbA1c by 1-1.8) and induce a 4-5 kg weight loss. Both medications have similar adverse effects on the gastrointestinal system, resulting in weight loss of 7-12 kg and reduction of HbA1c by 2.0-2.4, with both drugs experiencing similar side effects, such as nausea and vomiting, which are mostly moderate and dose-dependent. Emerging data also suggest other benefits, including, but not limited to, improved hepatic steatosis with semaglutide and potential cardiovascular advantages with tirzepatide, which translate to the fact that these two drugs offer weight loss and glycemic control with high tolerance. Semaglutide has the advantage of oral administration and demonstrated cardiovascular safety whereas tirzepatide demonstrates slightly improved metabolic outcomes. To patients with type 2 diabetes mellitus, the drugs represent the dawn of a new age of personalized and comprehensive metabolic treatment.